Amitkumar Mehta

5.6k total citations
114 papers, 1.3k citations indexed

About

Amitkumar Mehta is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Amitkumar Mehta has authored 114 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Pathology and Forensic Medicine, 55 papers in Oncology and 35 papers in Genetics. Recurrent topics in Amitkumar Mehta's work include Lymphoma Diagnosis and Treatment (58 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (32 papers). Amitkumar Mehta is often cited by papers focused on Lymphoma Diagnosis and Treatment (58 papers), CAR-T cell therapy research (43 papers) and Chronic Lymphocytic Leukemia Research (32 papers). Amitkumar Mehta collaborates with scholars based in United States, France and United Kingdom. Amitkumar Mehta's co-authors include Nilanjan Ghosh, Andres Forero‐Torres, Joanna Zurko, Nancy L. Bartlett, Alex F. Herrera, Izidore S. Lossos, Leo I. Gordon, Javier Muñoz, Matthew A. Lunning and Michael Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Amitkumar Mehta

108 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amitkumar Mehta United States	20	834	515	349	240	213	114	1.3k
W. Christopher Ehmann United States	18	762 0.9×	318 0.6×	600 1.7×	216 0.9×	238 1.1×	43	1.4k
Anne Beaven United States	19	511 0.6×	556 1.1×	209 0.6×	186 0.8×	170 0.8×	89	956
Manali Kamdar United States	17	1.1k 1.3×	818 1.6×	211 0.6×	149 0.6×	286 1.3×	90	1.4k
Jan Maciej Zaucha Poland	20	443 0.5×	428 0.8×	448 1.3×	258 1.1×	374 1.8×	137	1.7k
Tycel Phillips United States	22	899 1.1×	956 1.9×	367 1.1×	232 1.0×	554 2.6×	149	1.6k
Javier Muñoz United States	23	1.2k 1.5×	886 1.7×	333 1.0×	357 1.5×	545 2.6×	133	1.8k
Julia Stieglmaier Germany	15	938 1.1×	387 0.8×	364 1.0×	237 1.0×	141 0.7×	24	1.4k
Matthew Mei United States	20	523 0.6×	391 0.8×	121 0.3×	216 0.9×	292 1.4×	108	1.1k
Lynn Navale United States	17	1.7k 2.0×	863 1.7×	317 0.9×	387 1.6×	212 1.0×	59	2.1k
Carsten Zwick Germany	15	525 0.6×	616 1.2×	494 1.4×	424 1.8×	256 1.2×	32	1.3k

Countries citing papers authored by Amitkumar Mehta

Since Specialization

Citations

This map shows the geographic impact of Amitkumar Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amitkumar Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amitkumar Mehta more than expected).

Fields of papers citing papers by Amitkumar Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amitkumar Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amitkumar Mehta. The network helps show where Amitkumar Mehta may publish in the future.

Co-authorship network of co-authors of Amitkumar Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Amitkumar Mehta. A scholar is included among the top collaborators of Amitkumar Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amitkumar Mehta. Amitkumar Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations

Schett, Georg, Tatyana Feldman, Jeremy S. Abramson, et al.. (2024). P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases. SHILAP Revista de lepidopterología. A115–A116. 2 indexed citations

Zinzani, Pier Luigi, Gilles Salles, Alison J. Moskowitz, et al.. (2024). Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Advances. 8(10). 2400–2404. 4 indexed citations

Mehta, Amitkumar, Leslie Popplewell, Graham P. Collins, et al.. (2024). Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial. Blood Advances. 8(22). 5855–5863. 13 indexed citations

Asch, Adam S., Leslie Popplewell, Graham P. Collins, et al.. (2024). Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 8(22). 5864–5874. 6 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.

Maakaron, Joseph, Dipenkumar Modi, Matthew Mei, et al.. (2024). Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study. Blood. 144(Supplement 1). 3052–3052. 2 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma Myeloma & Leukemia. 24. S212–S212. 1 indexed citations

Khanal, Rashmi, Amitkumar Mehta, Joseph Maly, et al.. (2023). AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7529–7529. 3 indexed citations

10.

Kim, Y. H., M. Bagot, Pablo L. Ortiz‐Romero, et al.. (2023). LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY. Hematological Oncology. 41(S2). 196–197. 2 indexed citations

11.

Mehta, Amitkumar, et al.. (2023). Breaking barriers: Effective interventions amplifying minority participation in cancer clinical trials.. JCO Oncology Practice. 19(11_suppl). 201–201. 1 indexed citations

12.

Flowers, Christopher R., Matthew J. Matasar, Alex F. Herrera, et al.. (2023). Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Haematologica. 109(4). 1194–1205. 4 indexed citations

13.

Assouline, Sarit, Amitkumar Mehta, Tycel Phillips, et al.. (2021). TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. Blood. 138(Supplement 1). 2488–2488. 4 indexed citations

14.

Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208. 3 indexed citations

15.

Strati, Paolo, Eliza A. Hawkes, Nilanjan Ghosh, et al.. (2021). Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood. 138(Supplement 1). 2493–2493. 15 indexed citations

16.

Bartlett, Nancy L., Alex F. Herrera, Eva Domingo‐Doménech, et al.. (2020). A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 136(21). 2401–2409. 107 indexed citations

17.

May, Jori E., et al.. (2020). Co-Occurrence of Familial Hemophagocytic Lymphohistiocytosis Type 2 and Chronic Active Epstein-Barr Virus in Adulthood. The American Journal of the Medical Sciences. 361(3). 388–393. 5 indexed citations

18.

Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241. 89 indexed citations

19.

Mooney, David, Ravi Kumar Paluri, Amitkumar Mehta, Jatinder Goyal, & Guru Sonpavde. (2014). Update in Systemic Therapy of Urologic Malignancies. Postgraduate Medicine. 126(1). 44–54. 7 indexed citations

20.

Mehta, Amitkumar, et al.. (2013). Heparin induced thrombocytopenia: review. Expert Review of Hematology. 6(4). 419–428. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact